On July 31, BrightSpring Health Services Inc. declined 9.65% in regular trading, trading at approximately $62.995/share, with turnover of $62.98 million. The sell-off came despite the company reporting Q2 results that beat expectations across the board.

The company reported Q2 adjusted EPS of $0.45, surpassing the analyst consensus of $0.40 by 12.5%, representing a 104.55% year-over-year increase from $0.22. Revenue reached $3.87 billion, beating expectations of $3.66 billion and up from $3.15 billion a year earlier. The company also raised its full-year revenue guidance to $15.10-$15.43 billion from $14.73-$15.23 billion previously, exceeding the analyst estimate of $15.07 billion.

However, the stock had rallied substantially ahead of earnings. Throughout July, multiple investment banks raised price targets — UBS to $85, Morgan Stanley to $80, Guggenheim initiated at $81, and Raymond James at $80. The stock surged 5.07% on July 30 alone, reaching $72.885. Despite the strong beat-and-raise quarter, the prior run-up left limited upside, triggering a classic profit-taking pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)